These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37819778)

  • 1. Correction to "Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study".
    J Clin Endocrinol Metab; 2024 Jan; 109(2):e880. PubMed ID: 37819778
    [No Abstract]   [Full Text] [Related]  

  • 2. Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study.
    Biscarini F; Masetti G; Muller I; Verhasselt HL; Covelli D; Colucci G; Zhang L; Draman MS; Okosieme O; Taylor P; Daumerie C; Burlacu MC; Marinò M; Ezra DG; Perros P; Plummer S; Eckstein A; Salvi M; Marchesi JR; Ludgate M
    J Clin Endocrinol Metab; 2023 Jul; 108(8):2065-2077. PubMed ID: 36683389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The thyroid, the eyes and the gut: a possible connection.
    Covelli D; Ludgate M
    J Endocrinol Invest; 2017 Jun; 40(6):567-576. PubMed ID: 28063079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy.
    Shi TT; Xin Z; Hua L; Wang H; Zhao RX; Yang YL; Xie RR; Liu HY; Yang JK
    J Endocrinol Invest; 2021 Feb; 44(2):297-310. PubMed ID: 32449092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience.
    Prummel MF; Bakker A; Wiersinga WM; Baldeschi L; Mourits MP; Kendall-Taylor P; Perros P; Neoh C; Dickinson AJ; Lazarus JH; Lane CM; Heufelder AE; Kahaly GJ; Pitz S; Orgiazzi J; Hullo A; Pinchera A; Marcocci C; Sartini MS; Rocchi R; Nardi M; Krassas GE; Halkias A
    Eur J Endocrinol; 2003 May; 148(5):491-5. PubMed ID: 12720530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
    Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U;
    Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role and molecular mechanism of gut microbiota in Graves' orbitopathy.
    Li Y; Luo B; Tong B; Xie Z; Cao J; Bai X; Peng Y; Wu Y; Wang W; Qi X
    J Endocrinol Invest; 2023 Feb; 46(2):305-317. PubMed ID: 35986869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease.
    Masetti G; Moshkelgosha S; Köhling HL; Covelli D; Banga JP; Berchner-Pfannschmidt U; Horstmann M; Diaz-Cano S; Goertz GE; Plummer S; Eckstein A; Ludgate M; Biscarini F; Marchesi JR;
    Microbiome; 2018 May; 6(1):97. PubMed ID: 29801507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.
    Perros P; Žarković MP; Panagiotou GC; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi AM; Nardi M; Brix TH; Covelli D; Daumerie C; Eckstein AK; Fichter N; Ćirić S; Hegedüs L; Kahaly GJ; Konuk O; Lareida JJ; Okosieme OE; Leo M; Mathiopoulou L; Clarke L; Menconi F; Morris DS; Orgiazzi J; Pitz S; Salvi M; Muller I; Knežević M; Wiersinga WM; Currò N; Dayan CM; Marcocci C; Marinò M; Möller L; Pearce SH; Törüner F; Bernard M;
    J Endocrinol Invest; 2020 Dec; 43(12):1717-1722. PubMed ID: 32474767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of common practices among oculofacial surgeons in the Asia-Pacific region: Graves' orbitopathy.
    Sundar G; Chiam N; Lun K; Koh V
    Orbit; 2014 Oct; 33(5):319-25. PubMed ID: 25121573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiome and Graves' Orbitopathy.
    Masetti G; Ludgate M
    Eur Thyroid J; 2020 Dec; 9(Suppl 1):78-85. PubMed ID: 33511088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.
    Perros P; Hegedüs L; Bartalena L; Marcocci C; Kahaly GJ; Baldeschi L; Salvi M; Lazarus JH; Eckstein A; Pitz S; Boboridis K; Anagnostis P; Ayvaz G; Boschi A; Brix TH; Currò N; Konuk O; Marinò M; Mitchell AL; Stankovic B; Törüner FB; von Arx G; Zarković M; Wiersinga WM
    Orphanet J Rare Dis; 2017 Apr; 12(1):72. PubMed ID: 28427469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the Microbiota in Graves' Disease and Graves' Orbitopathy.
    Hou J; Tang Y; Chen Y; Chen D
    Front Cell Infect Microbiol; 2021; 11():739707. PubMed ID: 35004341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
    Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
    Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the gut microbiota of patients with Graves' orbitopathy according to severity grade.
    Zhang Q; Tong B; Xie Z; Li Y; Li Y; Wang L; Luo B; Qi X
    Clin Exp Ophthalmol; 2023 Nov; 51(8):808-821. PubMed ID: 37674301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
    Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
    Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with severity of orbitopathy in patients with Graves' disease.
    Nabi T; Rafiq N
    Taiwan J Ophthalmol; 2020; 10(3):197-202. PubMed ID: 33110751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.